Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...

Calidi Biotherapeutics, a clinical-stage biotechnology company, disclosed on January 8, 2025, its entry into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. The agreement pertains to ...

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

Epithelial tissues are in constant interaction with their environment. Maintaining their functionality requires dynamic ...

Medical advancements make early-detected cancers more manageable and treatable, with immunotherapy and CAR T cell therapy ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

During the development of the olfactory epithelium (OE), olfactory sensory neurons (OSNs) express only one member of the odorant receptor (OR) gene family, and O ...

This is because the cell is being reverted back to a normal-like state, rather than destroyed altogether. The discovery could reduce the nasty side effects associated with cancer treatment (Getty ...

Some people with advanced castrate-resistant prostate cancer now have a new option: PSMA lutetium-177, also known as lutetium Lu 177 vipivotide tetraxetan, a radiopharmaceutical.